CAMBRIDGE, Mass., January 4, 2023 — Korro Bio, Inc. , a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 41 st Annual J.P.
Venkat Krishnamurthy appointed Senior Vice President, Head of Platform Stephanie Engels appointed Senior Vice President, Head of People and Culture CAMBRIDGE, Mass., November 8, 2022— Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic
CAMBRIDGE, Mass., June 6, 2022 — Korro Bio, Inc. , a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New
Financing led by Eventide Asset Management with participation from a strong syndicate of new and existing investors Funding will advance Korro’s proprietary editing platform that co-opts endogenous human RNA editing system Advancing a novel class of RNA editing drug candidates for rare and
CAMBRIDGE, Mass., January 5, 2022 — Korro Bio, Inc. , a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 40 th Annual J.P.
CAMBRIDGE, Mass., November 22, 2021 — Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences, as
CAMBRIDGE, Mass., August 31, 2021 — Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Wells Fargo Healthcare Conference and participate in a
CAMBRIDGE, Mass., May 24, 2021 — Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on June 4, 2021, at
CAMBRIDGE, Mass., May 11, 2021 — Korro Bio, Inc ., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Vineet Agarwal as Chief Financial Officer. He joins Korro from J.P. Morgan Chase & Co., where he most recently served as
CAMBRIDGE, Mass., April 1, 2021 — Korro Bio, Inc ., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Howard Stern, M.D., Ph.D. as Chief Scientific Officer. Dr. Stern is a seasoned biotechnology executive with extensive
